Get all premium features to the best stock analysis tool

Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has extended its review of the New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026.

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater patient availability

Lantheus Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lantheus Holdings, Inc. - LNTH

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Lantheus Holdings, Inc. (NasdaqGM: LNTH). In August of 2025, contrary to the Company's prior optimistic outlook for the growth potential of its flagship product, Pylarify, the Company disclosed an 8% year-over-year decline in Pylarify revenue, as well as cuts to its.

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its fourth quarter and full year ended December 31, 2025.